1. Embryo-fetal toxicity.
2. Venous and arterial thromboembolism.
3. Increased mortality in patients with multiple myeloma when pembrolizumab is added to a thalidomide analogue and dexamethasone.
4. Hematologic toxicity.
5. Hepatotoxicity.
6. Severe cutaneous adverse reactions.
7. Dizziness and confusional state.
8. Neuropathy.
9. Risk of second primary malignancies.
10. Tumor lysis syndrome.
11. Hypersensitivity reactions.